nifedipine has been researched along with Breast Neoplasms in 15 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested the efficacy of nifedipine to reverse acquired resistance to chemotherapy regimens containing doxorubicin or vinblastine or both in 12 patients with metastatic breast cancer." | 9.08 | Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine. ( Fraschini, G; Frye, D; Holmes, FA; Hortobagyi, GN; Lopez, A; Mavligit, G, 1997) |
| "Despite its intensive use in adjuvant breast cancer therapy for more than 30 years, the exact mechanisms of action of tamoxifen have not yet been fully characterized." | 7.69 | Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells. ( Bracke, M; Bruyneel, E; Castronovo, V; Charlier, C; Lechanteur, C; Mareel, M, 1996) |
| "We tested the efficacy of nifedipine to reverse acquired resistance to chemotherapy regimens containing doxorubicin or vinblastine or both in 12 patients with metastatic breast cancer." | 5.08 | Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine. ( Fraschini, G; Frye, D; Holmes, FA; Hortobagyi, GN; Lopez, A; Mavligit, G, 1997) |
| "Despite its intensive use in adjuvant breast cancer therapy for more than 30 years, the exact mechanisms of action of tamoxifen have not yet been fully characterized." | 3.69 | Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells. ( Bracke, M; Bruyneel, E; Castronovo, V; Charlier, C; Lechanteur, C; Mareel, M, 1996) |
| "The calcium channel antagonists (CCAs) amlodipine, diltiazem, and verapamil inhibited HT-39 human breast cancer cell proliferation in a concentration-dependent manner." | 3.68 | Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. ( Simpson, RU; Taylor, JM, 1992) |
| "Enhancements of cytotoxic effects of adriamycin (ADM) and vincristine (VCR) on PC-6 (lung cancer cell line) and Hattori (breast cancer cell line) were investigated by concomitant use of a calmodulin inhibitor: nicardipine, antiplatelet agents: oxyfedrine and trimethazidine and an antihypertensive agent: trichlormethiazide." | 3.67 | [Enhanced cytotoxic effect of Adriamycin and vincristine against PC-6 (human lung cancer cell line) and Hattori (human breast cancer cell line)]. ( Inoue, K; Mitsui, I; Mukaiyama, T; Ogawa, M; Terashima, M, 1985) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| "One of the most common signs of breast tumors is the presence of small deposits of calcium, known as microcalcifications." | 1.56 | Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment. ( Babula, P; Chovancova, B; Durinikova, E; Hudecova, S; Krizanova, O; Liskova, V; Matuskova, M; Miklikova, S; Novakova, M; Penesova, A; Sevcikova, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| Chovancova, B | 1 |
| Liskova, V | 1 |
| Miklikova, S | 1 |
| Hudecova, S | 1 |
| Babula, P | 1 |
| Penesova, A | 1 |
| Sevcikova, A | 1 |
| Durinikova, E | 1 |
| Novakova, M | 1 |
| Matuskova, M | 1 |
| Krizanova, O | 1 |
| Zhao, T | 1 |
| Guo, D | 1 |
| Gu, Y | 1 |
| Ling, Y | 1 |
| Riahi, N | 1 |
| Kefayat, A | 1 |
| Ghasemi, A | 1 |
| Asgarshamsi, M | 1 |
| Panjehpoor, M | 1 |
| Fassihi, A | 1 |
| Li, W | 1 |
| Shi, Q | 1 |
| Wang, W | 1 |
| Liu, J | 1 |
| Li, Q | 1 |
| Hou, F | 1 |
| Guo, DQ | 1 |
| Zhang, H | 1 |
| Tan, SJ | 1 |
| Gu, YC | 1 |
| Kretschy, N | 1 |
| Teichmann, M | 1 |
| Kopf, S | 1 |
| Atanasov, AG | 1 |
| Saiko, P | 1 |
| Vonach, C | 1 |
| Viola, K | 1 |
| Giessrigl, B | 1 |
| Huttary, N | 1 |
| Raab, I | 1 |
| Krieger, S | 1 |
| Jäger, W | 1 |
| Szekeres, T | 1 |
| Nijman, SM | 1 |
| Mikulits, W | 1 |
| Dirsch, VM | 1 |
| Dolznig, H | 1 |
| Grusch, M | 1 |
| Krupitza, G | 1 |
| Roger, S | 1 |
| Le Guennec, JY | 1 |
| Besson, P | 1 |
| Lenzhofer, R | 1 |
| Ganzinger, U | 1 |
| Rameis, H | 1 |
| Moser, K | 1 |
| Stewart, DJ | 1 |
| Evans, WK | 1 |
| Logan, D | 1 |
| Charlier, C | 1 |
| Bruyneel, E | 1 |
| Lechanteur, C | 1 |
| Bracke, M | 1 |
| Mareel, M | 1 |
| Castronovo, V | 1 |
| Holmes, FA | 1 |
| Lopez, A | 1 |
| Mavligit, G | 1 |
| Fraschini, G | 1 |
| Frye, D | 1 |
| Hortobagyi, GN | 1 |
| Moussalli, J | 1 |
| Cadranel, JF | 1 |
| Danel, B | 1 |
| Plantier, F | 1 |
| Benhamou, Y | 1 |
| Opolon, P | 1 |
| Taylor, JM | 1 |
| Simpson, RU | 1 |
| Terashima, M | 1 |
| Inoue, K | 1 |
| Mukaiyama, T | 1 |
| Mitsui, I | 1 |
| Ogawa, M | 1 |
2 reviews available for nifedipine and Breast Neoplasms
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
Calcium channel blockers and risk of breast cancer: a meta-analysis of 17 observational studies.
Topics: Adult; Aged; Antihypertensive Agents; Breast Neoplasms; Calcium Channel Blockers; Case-Control Studi | 2014 |
2 trials available for nifedipine and Breast Neoplasms
| Article | Year |
|---|---|
Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Heart; Humans; Middle | 1983 |
Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; B | 1997 |
11 other studies available for nifedipine and Breast Neoplasms
| Article | Year |
|---|---|
Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment.
Topics: Antineoplastic Agents, Immunological; Apoptosis; Breast Neoplasms; Calcium Channel Blockers; Calcium | 2020 |
Nifedipine stimulates proliferation and migration of different breast cancer cells by distinct pathways.
Topics: Breast Neoplasms; Calcium Channels; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellul | 2017 |
Design, Synthesis and Molecular Docking Studies of Some Tetrahydropyrimidine Derivatives as Possible Fascin Inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Drug Des | 2019 |
Nifedipine promotes the proliferation and migration of breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Express | 2014 |
In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acetohexamide; Antineoplastic Combined Chemotherapy Prot | 2013 |
Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line.
Topics: Breast Neoplasms; Calcium Channel Blockers; Cell Division; Cell Line, Tumor; Cell Survival; Diltiaze | 2004 |
Addition of pentoxifylline plus nifedipine to chemotherapy in patients with cisplatin-resistant cancers of the lung and other sites.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Evaluation; Drug R | 1994 |
Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1996 |
[Partially reversible secondary achalasia after thoracic radiation. Value of nifedipine].
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Esophageal Achalasia; Female; Humans; Nifedipine; Radiation | 1992 |
Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse.
Topics: Amlodipine; Animals; Breast Neoplasms; Calcium; Calcium Channel Blockers; Cell Division; Culture Med | 1992 |
[Enhanced cytotoxic effect of Adriamycin and vincristine against PC-6 (human lung cancer cell line) and Hattori (human breast cancer cell line)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; | 1985 |